Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
マイクロRNAの測定方法、並びに、がん治療剤及びこれを含有するがん治療のための医薬組成物
Document Type and Number:
Japanese Patent JP6745071
Kind Code:
B2
Abstract:
The present inventors have found microRNAs which are strongly associated with stabilization of NRF2 in tumors, and an object of the present invention is to provide means for utilizing such miRNAs for the diagnosis and treatment of cancer. The inventors conducted screening of 470 microRNAs in a microRNA library by use of HeLa cells. As a result, 8 miRNAs each exhibiting a large decrease in miRNA activity as compared with a control miRNA, and 8 miRNAs each exhibiting a large increase in miRNA activity as compared with a control miRNA, were identified. The inventors have found that the NRF2 activation in the living body, in particular tumor cells, can be detected by use of the thus-identified miRNAs, whereby malignancy of a tumor, or the like can be differentiated. The inventors have also found that a nucleic acid including a miRNA sequence associated with reduction in the aforementioned ARE activity can be used as a cancer therapeutic agent.

Inventors:
Joji Inazawa
Jun Inoue
Shinsuke Yamamoto
Tatsuyuki Kono
Kenichi Ozaki
Application Number:
JP2018094747A
Publication Date:
August 26, 2020
Filing Date:
May 16, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
Tokyo Medical And Dental University, Medical Hospital
International Classes:
C12Q1/6851; A61K31/7105; A61K31/713; A61K33/243; A61K45/00; A61K48/00; A61P1/00; A61P1/02; A61P1/04; A61P1/16; A61P11/00; A61P15/00; A61P17/00; A61P19/00; A61P21/00; A61P35/00; C12Q1/686
Domestic Patent References:
JP2012184230A
JP2008519606A
Foreign References:
WO2011111715A1
WO2009044899A1
WO2012174282A1
WO2009136501A1
WO2012121178A1
Other References:
Cancer Res.,2008年 3月 1日,Vol. 68, No. 5,p. 1303-1309
Cancer Cell,2012年 7月10日,Vol. 22,p. 66-79
Cancer Res.,2009年 3月15日,Vol. 69, No. 6,p. 2425-2434
Carcinogenesis,2010年,vol. 31, no. 8,p. 1354-1359,Table. S1
Attorney, Agent or Firm:
Mitsuharu Shimura